In daily diagnostic routines, assays to identify PIK3CA mutations in patients with HER2-negative, PIK3CA-mutated, advanced or metastatic BC and patient-specific multiplexed cancer alteration analysis methods for targeted digital sequencing (TARDIS) for the identification of patients at risk of recurrence are well-known applications of LB [29,30]. This evidence concerns the gene PIK3CA and breast cancer.